Abstract
Background
Oral L-threo-3,4-dihydroxyphenylserine (L-DOPS), a synthetic catechol amino acid, increases standing blood pressure and improves standing ability in patients with neurogenic orthostatic hypotension, by conversion of L-DOPS to norepinephrine (NE) outside the brain. This study assessed the pharmacokinetics of L-DOPS, NE, and dihydroxyphenylglycol (DHPG), the main neuronal metabolite of NE, in patients with primary chronic autonomic failure from pure autonomic failure (PAF) or multiple system atrophy (MSA).
Methods
In 5 MSA and 4 PAF patients, antecubital venous blood was drawn during supine rest and plasma levels of catechols measured at various times for 48 hours after a single oral dose of 400 mg of L-DOPS.
Results
Plasma L-DOPS peaked at 1.9 µg/ml (9 µmol/L) about 3 hours after drug administration, followed by a monoexponential decline with a half-time of 2–3 hours in both patient groups. Plasma NE and DHPG also peaked at about 3 hours, but at much lower concentrations (4 and 42 nmol/L). Compared to the MSA group, the PAF group had a smaller calculated volume of distribution of L-DOPS and up to 10-fold lower plasma NE levels at all time points. Plasma NE was above baseline in MSA even at 48 hours after L-DOPS.
Conclusions
The relatively long half-time for disappearance of L-DOPS compared to that of NE explains their very different attained plasma concentrations. The similar NE and DHPG responses in PAF and MSA suggests production of NE from LDOPS mainly in non-neuronal cells. Persistent elevation of plasma NE in MSA suggests residual release of NE from sympathetic nerves.
Similar content being viewed by others
References
Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, Nardin R, Freeman R (2003) Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation 108:724–7283
Goldstein DS, Polinsky RJ, Garty M, Robertson D, Brown RT, Biaggioni I, Stull R, Kopin IJ (1989) Patterns of plasma levels of catechols in neurogenic orthostatic hypotension. Ann Neurol 26:558–563
Polinsky RJ, Kopin IJ, Ebert MH, Weise V (1981) Pharmacologic distinction of different orthostatic hypotension syndromes. Neurology 31:1–7
Ziegler MG, Lake CR, Kopin IJ (1977) The sympathetic-nervous-system defect in primary orthostatic hypotension. N Engl J Med 296:293–297
Mathias CJ (1995) The classification and nomenclature of autonomic disorders—ending chaos, resolving conflict and hopefully achieving clarity. Clin Auton Res 5:307–310
Holmes C, Eisenhofer G, Goldstein DS (1994) Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J Chromatog B Biomed Applic 653:131–138
Hardie RJ, Malcolm SL, Lees AJ, Stern GM, Allen JG (1986) The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson’s disease who exhibit on-off fluctuations. Br J Clin Pharmacol 22:429–436
Nutt JG, Woodward WR (1986) Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 36:739–744
Kempster PA, Frankel JP, Bovingdon M, Webster R, Lees AJ, Stern GM (1989) Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson’s disease. J Neurol Neurosurg Psychiatry 52:718–723
Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A (1993) Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson’s disease. Neurology 43:367–371
Goldstein D, Horwitz D, Keiser HR, Polinsky RJ, Kopin IJ (1983) Plasma l-[3H]norepinephrine, d-[14C]norepinephrine, and d,l-[3H]isoproterenol kinetics in essential hypertension. J Clin Invest 72:1748–1758
Grossman E, Chang PC, Hoffman A, Tamrat M, Kopin IJ, Goldstein DS (1991) Tracer norepinephrine kinetics: dependence on regional blood flow and the site of infusion. Am J Physiol 260:R946–R952
Goldstein DS, Holmes C, Cannon RO III, Eisenhofer G, Kopin IJ (1997) Sympathetic cardioneuropathy in dysautonomias. N Engl J Med 336:696–702
Jennings G, Korner P, Willett I, Dudley F, Hasking G, Anderson W, Lambert G (1988) Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 11:3–20
Crout JR, Sjoerdsma A (1964) Turnover and metabolism of catecholamines in patients with pheochromocytoma. J Clin Invest 43:94–102
Spector S, Tarver J, Berkowitz B (1972) Effects of drugs and physiological factors in the disposition of catecholamines in blood vessels. Pharmacol Rev 24:191–202
Goldstein DS (2003) Dysautonomia in Parkinson’s disease: neurocardiological abnormalities. Lancet Neurol 2:669–676
Cannon WB (1939) A law of denervation. Am J Med Sci 198:737–750
Davies B, Sudera D, Sagnella G, Marchesi-Saviotti E, Mathias C, Bannister R, Sever P (1982) Increased numbers of alpha receptors in sympathetic denervation supersensitivity in man. J Clin Invest 69:779–784
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Goldstein, D.S., Holmes, C., Kaufmann, H. et al. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clin Auton Res 14, 363–368 (2004). https://doi.org/10.1007/s10286-004-0221-z
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/s10286-004-0221-z